抗VEGF药物治疗血管源性眼病的基础与临床研究进展  

Advance of substructure and clinical research about anti-VEGF therapy for ocular vascular disease

作　　者：陈辛元[1] 叶俊杰[1] 

机构地区：[1]中国医学科学院中国协和医科大学北京协和医院眼科,北京100730

出　　处：《眼科研究》2008年第9期708-712,共5页Chinese Ophthalmic Research

摘　　要：许多人类血管源性眼病均与血管内皮生长因子(VEGF)有关。近年来玻璃体腔注射抗VEGF药物治疗血管源性眼病逐渐应用于临床,就macugen,lucentis和avastin三种抗VEGF药物的基础研究、临床应用进展及不良反应情况进行综述,从生物学特性、临床疗效及应用前景等方面分析比较三种药物的共同点与特异性。Vascular endothelial growth factor （VEGF） had been implicated as the major factor in the induction of ocular vascular disease, such as advanced age-related macular degeneration （AMD）, proliferative diabetic retinopathy （PDR）, neovascularization secondary to retinal vein occlusion （ RVO ） , etc.. Intravitreal anti-VEGF injection had been used for treating ocular vascular disease generally, especially for AMD complicated with choroidal neovascularization. Application of VEGF can stabilize visual acuity and even improve visual acuity. The advance in basic research, clinical application and adverse effects of anti-VEGF therapy including macugen,lucentis and avastin, are reviewed. The biology feature, clinic efficacy and perspection of the three drugs are analyzed and compared.

关 键 词：血管内皮生长因子 MACUGEN LUCENTIS AVASTIN 玻璃体腔注药 

分 类 号：R771.3[医药卫生—眼科]